Take your best guess and try to diagnose this 9-year-old girl's linear eruption on the back of her left thigh and leg. Stay tuned for the full case presentation and correct diagnosis! Welcome to this ...

Walker and Harris emphasize the importance of early hearing loss detection, screening, and intervention to support optimal child development. At the 2025 NAPNAP National Conference in Chicago, Camille ...

The PANDAS/PANS questionnaire is based on symptoms and comorbidities described in the literature and is a self-report completed by parents of children younger than 18. Investigators examined the ...

Peter S. Jensen, MD, discusses the risks and benefits of social media use by children, emphasizing the need for parental oversight and national guidelines. Social media use among children and ...

Danielle Van Damme, DNP, CPNP-AC, discussed key updates from the 2024 IDSA guideline on diagnosing complicated intra-abdominal infections, emphasizing ultrasound as the preferred imaging modality. At ...

The federal agencies are encouraging companies to develop new infant formulas and clarify opportunities to inform consumers about formula ingredients. The FDA and the US Department of Health and Human ...

Pediatricians face rising demands in specialty care and mental health, with programs such as REACH helping them manage these challenges. General pediatric providers and pediatric specialists across ...

Karen Y. Capusan, DNP, CPNP-PC, explored RSV’s shifting epidemiology, seasonal trends, and new vaccines’ role in reducing hospitalizations at the 2025 NAPNAP National Conference. At the 2025 NAPNAP ...

Prior to approval on February 14, 2025, the only FDA approved vaccine for chikungunya protection was indicated for 18 years and up. On March 18, 2025, Bavarian Nordic A/S announced the US commercial ...

2025 immunization update: addressing vaccine hesitancy and catch-up vaccinations ...

2025 immunization update: addressing vaccine hesitancy and catch-up vaccinations ...

Results will be included an a final analysis of safety and efficacy data for CTx-1301, which will be included in a NDA submission with the FDA, stated Cingulate Inc.